INSMED INC Net Income (Loss) Available to Common Stockholders, Diluted
INSMED INC (INSM) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$163.56 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-05-07
- INSMED INC net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$163.56M.
- INSMED INC net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$328.49M.
- INSMED INC net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$370.02M.
- INSMED INC net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was -$321.69M.
- INSMED INC net income (loss) available to common stockholders, diluted for fiscal 2025 was -$1.28B.
- INSMED INC net income (loss) available to common stockholders, diluted for fiscal 2024 was -$913.77M.
- INSMED INC net income (loss) available to common stockholders, diluted for fiscal 2023 was -$749.57M.
- INSMED INC net income (loss) available to common stockholders, diluted for fiscal 2022 was -$481.53M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$163.56M 10-Q · filed 2026-05-07 | -$492.05M derived: sum of 2 quarters · filed 2026-05-07 | -$862.07M derived: sum of 3 quarters · filed 2026-05-07 | -$1.18B derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | -$328.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$698.51M derived: sum of 2 quarters · filed 2026-02-19 | -$1.02B derived: sum of 3 quarters · filed 2026-02-19 | -$1.28B 10-K · filed 2026-02-19 |
| 2025-09-30 | -$370.02M 10-Q · filed 2025-10-30 | -$691.71M derived: sum of 2 quarters · filed 2025-10-30 | -$948.29M 10-Q · filed 2025-10-30 | -$1.18B derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-06-30 | -$321.69M 10-Q · filed 2025-08-07 | -$578.27M 10-Q · filed 2025-08-07 | -$813.82M derived: sum of 3 quarters · filed 2026-05-07 | -$1.03B derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-03-31 | -$256.58M 10-Q · filed 2026-05-07 | -$492.13M derived: sum of 2 quarters · filed 2026-05-07 | -$712.65M derived: sum of 3 quarters · filed 2026-05-07 | -$1.01B derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$235.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$456.07M derived: sum of 2 quarters · filed 2026-02-19 | -$756.68M derived: sum of 3 quarters · filed 2026-02-19 | -$913.77M 10-K · filed 2026-02-19 |
| 2024-09-30 | -$220.52M 10-Q · filed 2025-10-30 | -$521.13M derived: sum of 2 quarters · filed 2025-10-30 | -$678.22M 10-Q · filed 2025-10-30 | -$864.28M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | -$300.61M 10-Q · filed 2025-08-07 | -$457.70M 10-Q · filed 2025-08-07 | -$643.76M derived: sum of 3 quarters · filed 2026-02-19 | -$802.69M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$157.09M 10-Q · filed 2025-05-08 | -$343.15M derived: sum of 2 quarters · filed 2026-02-19 | -$502.08M derived: sum of 3 quarters · filed 2026-02-19 | -$746.89M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$186.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$344.99M derived: sum of 2 quarters · filed 2026-02-19 | -$589.80M derived: sum of 3 quarters · filed 2026-02-19 | -$749.57M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$158.93M 10-Q · filed 2024-10-31 | -$403.74M derived: sum of 2 quarters · filed 2024-10-31 | -$563.51M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | -$244.81M 10-Q · filed 2024-08-08 | -$404.57M 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | -$481.53M 10-K · filed 2025-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |